These experiments measured the expression of the degranulation marker CD107a on CD56dim NK cells in PBMCs exposed to the MM.1R myeloma cell line in the absence or presence of the therapeutic anti-SLAMF7 antibody, elotuzumab. Here, SLAMF7 is linked to plasma cell myeloma.